| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Przemysław Błyszczuk | Q63890118 |
| P2093 | author name string | Zoltan Szekanecz | |
| P2860 | cites work | Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity | Q24630655 |
| EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update | Q30244903 | ||
| The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study | Q33892790 | ||
| The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases | Q34129198 | ||
| Validated methods for assessment of subclinical atherosclerosis in rheumatology | Q34164481 | ||
| Longterm outcomes and treatment after myocardial infarction in patients with rheumatoid arthritis. | Q34328320 | ||
| Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease | Q34684331 | ||
| Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies | Q34889152 | ||
| The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. | Q35092457 | ||
| The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. | Q35135831 | ||
| Population-based study of QT interval prolongation in patients with rheumatoid arthritis | Q35195539 | ||
| Association between anti-TNF therapy for rheumatoid arthritis and hypertension: a meta-analysis of randomized controlled trials | Q35599025 | ||
| Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study | Q35605663 | ||
| Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis | Q35669374 | ||
| The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease | Q35904678 | ||
| Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis | Q35953268 | ||
| Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. | Q36031031 | ||
| Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry | Q36071720 | ||
| Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction | Q37060522 | ||
| The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. | Q37074034 | ||
| Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis | Q37156561 | ||
| Vascular effects of biologic agents in RA and spondyloarthropathies | Q37630351 | ||
| Heart involvement in rheumatoid arthritis: systematic review and meta-analysis | Q38019111 | ||
| Diastolic dysfunction in rheumatoid arthritis: a meta-analysis and systematic review | Q38045857 | ||
| Heart involvement in rheumatoid arthritis: multimodality imaging and the emerging role of cardiac magnetic resonance | Q38115865 | ||
| Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. | Q38729061 | ||
| Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap. | Q39057277 | ||
| Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease | Q39378053 | ||
| Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor | Q39575097 | ||
| Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure | Q40299381 | ||
| Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. | Q40386790 | ||
| Prevalence and factors related to left ventricular systolic dysfunction in asymptomatic patients with rheumatoid arthritis. A prospective tissue Doppler echocardiography study | Q40922691 | ||
| Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type | Q41355924 | ||
| Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control study | Q41617609 | ||
| Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study | Q43686388 | ||
| Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? | Q45235877 | ||
| The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study | Q45792532 | ||
| Imaging patterns of heart failure in rheumatoid arthritis evaluated by cardiovascular magnetic resonance. | Q46002415 | ||
| Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. | Q46003173 | ||
| Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis | Q46075758 | ||
| Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid Arthritis: Insights From CMR T1 Mapping | Q46177831 | ||
| Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide | Q46246719 | ||
| Carotid plaque characteristics and disease activity in rheumatoid arthritis | Q46487876 | ||
| Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu | Q47849023 | ||
| Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). | Q47945239 | ||
| Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis | Q48949308 | ||
| Antimalarial-induced cardiomyopathy: a systematic review of the literature | Q49383501 | ||
| Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. | Q50196335 | ||
| The Relationship Between Cardiac Conduction Times, Cardiovascular Risk Factors, and Inflammation in Patients with Early Arthritis. | Q50759004 | ||
| Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. | Q52583114 | ||
| Absence of Fibrosis and Inflammation by Cardiac Magnetic Resonance Imaging in Rheumatoid Arthritis Patients with Low to Moderate Disease Activity. | Q52587395 | ||
| Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis | Q57387086 | ||
| Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis | Q57540217 | ||
| Baseline levels of c-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis : A ten-year followup study of a primary care-based inception cohort | Q57804967 | ||
| Serum levels of anticyclic citrullinated peptide antibodies, interleukin-6, tumor necrosis factor-α, and C-reactive protein are associated with increased carotid intima-media thickness: a cross-sectional analysis of a cohort of rheumatoid arthritis | Q58051983 | ||
| Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept | Q58557973 | ||
| Myocardial Inflammation, Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG PET-CT) is Associated with Disease Activity in Rheumatoid Arthritis | Q58574869 | ||
| Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis | Q61830824 | ||
| Plasma cytokine parameters and mortality in patients with chronic heart failure | Q73306471 | ||
| Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor | Q74364510 | ||
| Antirheumatic drug use and the risk of acute myocardial infarction | Q80016233 | ||
| Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation | Q80932706 | ||
| Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist | Q85451584 | ||
| Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study | Q90030533 | ||
| Diastolic dysfunction in rheumatoid arthritis patients with low disease activity | Q90419436 | ||
| Myocardial Microvascular Dysfunction in Rheumatoid ArthritisQuantitation by 13N-Ammonia Positron Emission Tomography/Computed Tomography | Q91017049 | ||
| Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis | Q91138372 | ||
| Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study | Q92051324 | ||
| Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry | Q92352701 | ||
| Low-Dose Methotrexate for the Prevention of Atherosclerotic Events | Q92980641 | ||
| Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial | Q93008188 | ||
| A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis | Q93083086 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 1 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| anti-inflammatory agent | Q581996 | ||
| myocardial ischemia | Q6947906 | ||
| P577 | publication date | 2020-01-01 | |
| P1433 | published in | RMD open | Q27726913 |
| P1476 | title | Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis | |
| P478 | volume | 6 |
Search more.